Wednesday, July 8, 2026

Patent intelligence · US

US 11655454

Method and apparatus for improved mesenchymal stem cell harvesting

granted A61KA61K35/28A61K35/32
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 26
Patent details — US 11655454
Jurisdiction
US
Status
granted
Grant date
May 23, 2023
Expiration
May 18, 2043
Applicant
Elite IP, LLC
Claims
4
CPC classes
A61K, A61K35/28, A61K35/32
View on Google Patents ↗

Quick answer

US 11655454 (Method and apparatus for improved mesenchymal stem cell harvesting) is held by Elite IP, LLC. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Elite IP, LLC
Grant date
Expiration
Claims
4
CPC classes
A61K, A61K35/28, A61K35/32

More from Elite IP, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12364693

    Methods of treating metabolic diseases with fused bicyclic pyrazoles

    Belite Bio, Inc · Expires Jul 17, 2045

    granted
  2. US 12295394

    Water-soluble additive composition

    SUMITOMO BAKELITE CO., LTD. · Expires May 8, 2045

    granted
  3. US 12116596

    Method and apparatus for improved mesenchymal stem cell harvesting

    Elite IP, LLC · Expires Oct 10, 2044

    granted
  4. US 12016853

    Methods of treating RBP4 related diseases with triazolopyridines

    Belite Bio, Inc · Expires Jun 20, 2044

    granted
  5. US 11951100

    Formulations of RBP4 inhibitors and methods of use

    Belite Bio, Inc · Expires Apr 4, 2044

    granted
  6. US 11723873

    Oral dosage form of ticagrelor and preparation method thereof

    Elite Pharmaceutical Solution Inc. · Expires Aug 10, 2043

    granted
  7. US 11684596

    Antidiabetic pharmaceutical compositions and preparation method thereof

    Elite Pharmaceutical Solution Inc. · Expires Jun 22, 2043

    granted

Frequently asked questions

What is US patent 11655454?

US 11655454 (Method and apparatus for improved mesenchymal stem cell harvesting) is held by Elite IP, LLC. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11655454?

Elite IP, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 11655454 expire?

Our index shows an expiration date of May 18, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.